Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02658487 · ClinicalTrials.gov registry record · Phase 2
Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia
A Phase 2 study, sponsored by Vanderbilt-Ingram Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
NCT02658487 is a Phase 2 study that has completed, run by Vanderbilt-Ingram Cancer Center. The registered enrollment target is 42 participants.
The verdict
NCT02658487, a Phase 2 study, has completed, sponsored by Vanderbilt-Ingram Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
Study Summary
This phase II trial studies how well vosaroxin and cytarabine work in treating patients with untreated acute myeloid leukemia. Drugs used in chemotherapy, such as vosaroxin and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Interventions
- DRUG Cytarabine
- DRUG Vosaroxin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2016-03 |
| Est. Completion | 2024-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02658487
The ClinicalTrials.gov registry entry for NCT02658487 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt-Ingram Cancer Center, which has 189 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cytarabine is the first listed.
NCT02658487 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02658487 about?
NCT02658487 is a clinical study titled "Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia". This phase II trial studies how well vosaroxin and cytarabine work in treating patients with untreated acute myeloid leukemia. Drugs used in chemotherapy, such as vosaroxin and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from d...
What is the current status of trial NCT02658487?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2016-03. Estimated completion is 2024-09.
What interventions are being tested in trial NCT02658487?
The interventions under investigation include: Cytarabine (DRUG), Vosaroxin (DRUG).
Who is sponsoring clinical trial NCT02658487?
This trial is sponsored by Vanderbilt-Ingram Cancer Center, which has 189 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.